Sanofi India LimitedQuarter ended 30.09.2026 Results & Financial Update
Sanofi India Limited: Quarter ended 30.09.2026 standalone results and company financials – revenue ₹491.70 Cr, PAT ₹116.70 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Sanofi India price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Sanofi India Quarter ended 30.09.2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Sanofi India Limited reported revenue from operations of INR 491.7 crore for the quarter ended September 30, 2026, marking a 3.43% increase compared to INR 475.4 crore in the corresponding period of the previous year.
Profit after tax for the current quarter reached INR 116.7 crore, registering a significant year-on-year increase of 53.55% over INR 76.0 crore reported in Q3 FY25, supported by favorable product mix and disciplined cost management.
The diabetes portfolio served as a primary growth engine, delivering a high single-digit growth of 9% and reinforcing the company's market leadership in the diabetes injectable segment with a 55% value share.
Profit before tax before exceptional items rose 22% year-on-year to INR 157.7 crore compared to INR 102.3 crore in the same quarter last year (noting that the year-ago PBT included INR 27.3 crore of personnel separation costs).
Operating expenses, encompassing employee benefits and other expenses, declined 8% year-on-year during the quarter, reflecting operational efficiencies and disciplined cost control.
The board of directors declared an interim dividend of INR 75 per equity share of face value INR 10 for the financial year 2026, with November 5, 2026, fixed as the record date.
01 · Business model
What does Sanofi India do?
Sanofi India Limited operates in the pharmaceutical sector, offering a broad spectrum of healthcare solutions ranging from vaccines and specialty care to established medicines.
The company maintains a strong market presence in the diabetes injectable segment, anchored by key brands such as Lantus, Toujeo, Apidra, and Soliqua.
Manufacturing operations are anchored by its facility in Goa, which supplies products domestically and to over 24 international markets.
The company engages across the health spectrum through patient support programs, clinical trials, and community health initiatives spanning non-communicable disease screening and rare disease access programs.
02 · Historical context
What shaped the business before this quarter
The corresponding quarter ended September 30, 2025, included personnel separation costs of INR 27.3 crore classified as exceptional items.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter ended 30.09.2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹491.70 Cr | ₹475.40 Cr | ₹437.70 Cr |
| Total income | ₹497.20 Cr | ₹480.30 Cr | ₹443.90 Cr |
| Profit before tax | ₹157.70 Cr | ₹102.30 Cr | ₹112.30 Cr |
| Profit after tax | ₹116.70 Cr | ₹76.00 Cr | ₹83.50 Cr |
| EPS | ₹50.67 | ₹32.99 | ₹36.26 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 23.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 32.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹5.50 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
The insulin portfolio delivered high single-digit growth of 9% in Q3 FY26, driven by Lantus, Toujeo, Apidra, and the premium premix offering Soliqua.
The public sector business grew by 85% year-on-year, propelled by new accounts opened for innovative analogue segments.
Export sales achieved double-digit growth, underlining international resilience amid global headwinds.
What drove margins
Gross margin improvements were supported by a favorable product mix, a one-off reversal of provisions, and disciplined cost management.
Combined employee benefits and other expenses declined by 8% compared to the third quarter of 2025, bolstering profitability.
05 · Demand, customers & order book
Where demand is coming from
Maintained a 55% value share in the Indian diabetes injectable segment.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single business segment, namely the 'Pharmaceutical Business', as per regulatory reporting.
Geography and market mix
Domestic net sales grew by 2% while total net sales grew by 4% year-on-year; the Goa manufacturing site supplies domestic markets and over 24 countries globally.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
World-class manufacturing site in Goa produces pharmaceuticals for patients in India and more than 24 international countries.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Partnerships in Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments progressed and contributed to incremental market reach with stable revenues.
Employed a modernized go-to-market model across the diabetes injectable segment to support sustainable long-term value creation.
09 · Reported developments
What changed operationally
PAT grew by 53.55% year-on-year to INR 116.7 crore, supported by operational efficiencies.
10 · Items worth noticing
The line items that can distort a quick read
The year-ago quarter (Q3 FY25) included personnel separation costs of INR 27.3 crore, whereas no exceptional items were reported in Q3 FY26.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Reported low finance costs of INR 0.2 crore for the quarter, indicating a virtually debt-free capital structure.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Community and CSR Initiatives
The KiDS (Kids & Diabetes in School) program reached over 3,500 schools and educated 600,000 children across Goa, Uttar Pradesh, and Madhya Pradesh, alongside ongoing Medical Mobile Unit screenings.
13 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations increased from INR 437.7 crore in Q1 FY27 to INR 491.7 crore in Q2 FY27, while PAT rose from INR 83.5 crore to INR 116.7 crore.
14 · Key Q&A
The quarter, answered directly
What does Sanofi India do?
Sanofi India Limited operates in the pharmaceutical sector, offering a broad spectrum of healthcare solutions ranging from vaccines and specialty care to established medicines.
What is the clearest takeaway from Quarter ended 30.09.2026?
Sanofi India Limited reported revenue from operations of INR 491.7 crore for the quarter ended September 30, 2026, marking a 3.43% increase compared to INR 475.4 crore in the corresponding period of the previous year.
What drove revenue or demand?
The insulin portfolio delivered high single-digit growth of 9% in Q3 FY26, driven by Lantus, Toujeo, Apidra, and the premium premix offering Soliqua.
What mattered most for margins or profitability?
Gross margin improvements were supported by a favorable product mix, a one-off reversal of provisions, and disciplined cost management.
What changed operationally beyond the headline numbers?
World-class manufacturing site in Goa produces pharmaceuticals for patients in India and more than 24 international countries.
What should the next disclosure help confirm?
Track the commercial traction and return on investment from strategic partnerships in cardiovascular, oral anti-diabetes, and central nervous system segments.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Partnership Performance: Track the commercial traction and return on investment from strategic partnerships in cardiovascular, oral anti-diabetes, and central nervous system segments.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.